Compounds > dibenzo(a,i)pyrene
Page last updated: 2024-11-05

dibenzo(a,i)pyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9106
CHEBI ID82314
MeSH IDM0075640

Synonyms (53)

Synonym
rcra waste number u064
rcra waste no. u064
1,2:7,8-dibenzpyrene
nsc 87521
1,2,7,8-dibenzopyrene
benzo(r,s,t)pentaphene
ccris 214
dibenzo(b,h)pyrene
3,4:9,10-dibenzpyrene
einecs 205-877-5
brn 1881370
benzo(rst)pentaphene
hsdb 4027
dibenz(a,i)pyrene
3,4:9,10-dibenzopyrene
dibenzo(a,i)pyrene
wln: l d6 b66 p666 2ab a & j
1,7,8-dibenzopyrene
3,9,10-dibenzopyrene
3,10-dibenzpyrene
db(a,i)p
nsc87521
dibenzo[a,i]pyrene
3,10-dibenzopyrene
nsc-87521
benzo[r,t]pentaphene
dibenzo-3,9,10-pyrene
dibenz[a,i]pyrene
benzo[rst]pentaphene
189-55-9
NCIOPEN2_009544
FT-0666421
C19223
unii-7fmi112d18
7fmi112d18 ,
AKOS015914060
dibenzo(a,i)pyrene [hsdb]
benzo(rst)pentacene
dibenzo(a,i)pyrene [iarc]
CHEBI:82314
DTXSID9059751
dibenzo-3,4,9,10-pyrene
[3,4:9,10]dibenzpyrene
3,4,9,10-dibenzopyrene
TUGYIJVAYAHHHM-UHFFFAOYSA-N
3,4,9,10-dibenzpyrene
dibenzo[a,i]pyrene 10 microg/ml in acetonitrile
Q26841007
hexacyclo[10.10.2.02,7.09,23.014,19.020,24]tetracosa-1(23),2,4,6,8,10,12,14,16,18,20(24),21-dodecaene
dibenz[a,i]pyrene 10 microg/ml in acetonitrile
dibenz[a,i]pyrene 10 microg/ml in isooctane
CS-0085882
HY-124211

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Via intratracheal instillation, male CD rats (6/group) were dosed 3 times with BA, DBA, DBP or DBAC in a 24-h interval."( Induction of in vivo DNA adducts by 4 industrial by-products in the rat-lung-cell system.
Cutler, D; Ong, T; Stewart, JD; Whong, WZ, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ortho- and peri-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (37.50)18.7374
1990's4 (25.00)18.2507
2000's4 (25.00)29.6817
2010's2 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.27 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzo(a)pyrene
Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke.. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings.		2.4420ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
1,2,5,6-dibenzanthracene
1,2,5,6-dibenzanthracene: RN given refers to parent cpd		2.9240ortho-fused polycyclic arenemutagen
benz(a)anthracene
benz(a)anthracene: 4 fused rings of which one is angular in contrast to the linear NAPHTHACENES. tetraphene : An angular ortho-fused polycyclic arene consisting of four fused benzene rings.		2.6630ortho-fused polycyclic arene;
tetraphenes
dibenzo(a,h)pyrene
dibenzo(a,h)pyrene: structure given in first source		2.8940ortho- and peri-fused polycyclic arene
dibenzo(a,l)pyrene
dibenzo(a,l)pyrene: structure in first source		210ortho- and peri-fused polycyclic arenehuman metabolite;
mutagen
indeno(1,2,3-cd)pyrene
indeno(1,2,3-cd)pyrene: structure in first source		2.0610pyrenes
7h-dibenzo(c,g)carbazole
[no description available]		2.0610carbazoles
benzo(j)fluoranthene
benzo(j)fluoranthene: dihydrodiol metabolites identified as mutagens; structure given in first source		2.0610naphthalenes
benzo(b)fluoranthene
benzo[b]fluoranthene : An ortho- and peri-fused polycyclic arene that consists of a benzene ring fused with a acephenanthrylene ring.		2.0610ortho- and peri-fused polycyclic arenemutagen
benzo(k)fluoranthene
[no description available]		2.0610naphthalenes
picene
picene: structure given in first source. picene : An ortho-fused polycyclic arene consisting of five fused benzene rings. It is obtained during the distillation of petroleum.		210ortho-fused polycyclic arene
dibenzacridine
dibenzacridine: RN given refers to dibenz(a,j)acridine		2.4220
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.4220acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
alpha-naphthoflavone
alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).		1.9610extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist;
aryl hydrocarbon receptor antagonist;
EC 1.14.14.14 (aromatase) inhibitor
5-methylchrysene
5-methylchrysene: methylchrysenes in tobacco smoke are suspected to contribute to tumorigenicity of this inhalant; RN given refers to unlabeled cpd; structure		2.0610carbopolycyclic compound
1-nitropyrene
[no description available]		7.420nitroarenecarcinogenic agent
chlorodiphenyl (54% chlorine)
Chlorodiphenyl (54% Chlorine): A mixture of polychlorinated biphenyls that induces hepatic microsomal UDP-glucuronyl transferase activity towards thyroxine.. Aroclor 1254 : A mixture of polychlorobiphenyls of unspecified composition, containing 54% chlorine (X = Cl or H).		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatocellular Carcinoma
[description not available]		02.0510
Cancer of Liver
[description not available]		02.0510
Experimental Hepatoma
[description not available]		02.0510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0510
Benign Neoplasms
[description not available]		02.3820
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.3820
Cancer of Lung
[description not available]		02.0210
Lung Neoplasms
Tumors or cancer of the LUNG.		02.0210
Carcinoma, Epidermoid
[description not available]		02.4220
Cancer of Mouth
[description not available]		02.0410
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.4220
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.0410
Experimental Neoplasms
[description not available]		02.6530
Cancer of Skin
[description not available]		02.3620
Cocarcinogenesis
The combination of two or more different factors in the production of cancer.		01.9610
Skin Neoplasms
Tumors or cancer of the SKIN.		02.3620
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.420
Tracheal Neoplasms
New abnormal growth of tissue in the TRACHEA.		0210